TD Cowen Maintains Buy on Sage Therapeutics, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Ritu Baral maintains a Buy rating on Sage Therapeutics (NASDAQ:SAGE) but lowers the price target from $30 to $16.
April 18, 2024 | 11:49 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TD Cowen maintains a Buy rating on Sage Therapeutics but lowers the price target from $30 to $16.
The reduction in the price target by TD Cowen, despite maintaining a Buy rating, could lead to a negative short-term sentiment among investors, potentially causing a decrease in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100